Introduction {#sec0005}
============

The glioma accounting for about 45% of brain tumors, is the most common neoplasm of the central nervous system, representing 81% of malignant brain tumors in all of the world ([@bib0120]). It is classified according to the World Health Organization (WHO), according to their cell of origin, these include astrocytic tumors (astrocytoma grade I--IV), oligodendrogliomas (WHO grade II-III) and oligoastrocytomas (WHO grade II-III).

The glioblastoma multiforme (GBM) is one of the most malignant brain tumors in humans, accounting for 60% of all brain tumors in adult ([@bib0125]). The primary glioblastoma (*de novo*) is the most frequently and progress rapidly in elderly patients (\> 45 years), contrariwise the secondary glioblastoma develops from the anaplastic astrocytoma or low-grade diffuse astrocytoma in younger patients (\<45 years) ([@bib0110]).

The overall incidence is less than of 10/100 000 and It occurs more in males than in females ([@bib0065]). The cancer registry in Morocco has no data on the incidence of the central nervous system. On the other hand, GBM is associated with a poor prognosis.Despite aggressive surgery, radiation, and chemotherapies with temozolomide, the average life of survival still ∼ 1 year ([@bib0050]). The progress in the treatment modalities, it remains incurable. Among the most frequently observed genetic abnormalities in glioblastoma multiforme are overexpression and amplification of epidermal growth factor receptor (EGFR) with or without activating mutation and loss of PTEN expression, IDH 1/2 and p53 genes mutation, and the loss of the arm 10q (Ines [@bib0040]). The consequences of altering the signaling pathways of these genes, cause uncontrolled cell proliferation, enhanced cell survival and decrease apoptosis ([@bib0030]).

The IDHs enzymes (IDH1, IDH2, and IDH3) play role in the citric acid cycle, convert isocitrate to α-ketoglutarate with the conversion of NAD + to NADH (Hanumantha Rao [@bib0085]). All mutation identified to date in the IDH1 gene are missense at R132 and at analogous (R172) in IDH2 ([@bib0110]). The studies demonstrated that these mutations are frequent in secondary (\>80%) than in primary (\<5%) ([@bib0110]).

The p53 gene has a five conserved region and encodes for a transcription factor protein (393 amino-acid), plays role in apoptosis, cell regulation, and DNA reparation ([@bib0160]). The P53 mutations are higher in secondary (\>90%) than in primary (\<35%) ([@bib0100]). Loss of the p53 gene in GBM is due to mutations in exons 5 and exon 8 or homozygous/heterozygous deletion of chromosome 17 ([@bib0100]). The mutations affected exon 8 of the p53 gene are missense at R273H (818 G \> A), and nonsense at R306X (916 C \> T).The other mutation in exon 5 localized at Q136X (406C \> T) ([@bib0070]).

The EGFR gene is located on chromosome 7p12, codes for a tyrosine kinase membrane receptor that is bound to the EGF ligand. This binding activates the dimerization and autophosphorylation receptor of the cytoplasmic domain ([@bib0180]). In Glioblastoma, mutations of EGFR affect exons 18-19-20 and 21 ([@bib0010]). The EGFR signaling pathways participate in cell cycle activation, cell survival, proliferation, angiogenesis, motility, adhesion and metastasis of tumor cells ([@bib0170]).

The aim of this study was to conduct a literature review of the literature on glioblastoma genetic studies conducted in Moroccan patients and to identify the characteristics of our population.

Methods {#sec0010}
=======

A comprehensive literature search was conducted via ScienceDirect and PubMed (the latest research update was held on May 15, 2018) to find research articles related to glioblastoma in Morocco, using the following search terms: Glioblastoma Morocco, Primary glioblastoma Morocco, secondary glioblastoma Morocco. No language restrictions were imposed in either database.

The following criteria were used for our review: research articles dealing with the genetics of glioblastoma in Morocco, including primary and secondary glioblastoma. The major reason for exclusion of studies was as follow: reviews, epidemiological articles or poster and studies without genetic assay or have not been done on the Moroccan population ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1Flow diagram of the study selection process.Fig. 1

Results {#sec0015}
=======

Results of the literature search {#sec0020}
--------------------------------

After extensive research in Pubmed and ScienceDirect, we founded 90 results. we selected 3 research articles based on the title and relationship with the genetic glioblastoma of Moroccan patients.

Results of selected articles {#sec0025}
----------------------------

The [Table 1](#tbl0005){ref-type="table"} shows the results of the three studies carried out in Morocco to determine the genetic characteristics of the Moroccan population.Table 1Frequency of IDH1, IDH2 and TP53 mutations in glioblastomas from selected studies.Table 1ArticlenIDH1\
Codons 132IDH2\
Codons 172P53\
Exons 5 & 8EGFR\
Exon 20GBMpGBMsGBMGBMpGBMsGBMGBMpGBMsGBMGBMpGBMsGBM[@bib0140]6512.36%NDND0 %NDNDNDNDND26.15%NDND[@bib0135]6236.75%NDND0 %NDNDNDNDNDNDNDND[@bib0070]34ND0%NDND0%NDND8,82%NDNDNDND[^1]

It was reported in these selected articles, after sequencing of 65 and 62 patients in two different studies performed by Senhaji et al, the IDH 1 gene mutation (codons 132) was found in 12.36% and 36.75% of patients with glioblastoma ([@bib0140], [@bib0135]). On the other hand, the study of Hilmani et al reported that there is no IDH 1 gene mutation among 34 patients with primary glioblastoma ([@bib0070]).

For the mutation at IDH level 2 (codons 172), the sequencing of 65 and 62 patients with GBM, did not revealed any mutation in these patients, the same results were found in primary glioblastoma samples by the Hilmani team ([@bib0070]).

The exons from 4 to 10 of the p53 gene were screened by sequencing in 34 cases with primary glioblastoma; the analysis revealed a mutation only in exons 5 and 8 with a frequency of 8.82% ([@bib0070]) ([Fig. 2](#fig0010){ref-type="fig"}).Fig. 2Genetic alteration in primary and secondary glioblastoma ([@bib0115]).Fig. 2

Analysis of EGFR expression (exon 20) in 34 GBM patients revealed overexpression of this gene in 26.15% of the samples ([@bib0140]).

Discussion {#sec0030}
==========

Numerous alterations have been associated with genetic glioblastomas, such as the IDH1 / 2 mutation, the loss of 10q heterozygosity, the p53 mutation, the MDM2 overexpression and the p16 ^ink4a^ deletion ([Fig. 1](#fig0005){ref-type="fig"}), but the mechanism leading to the development of glioblastoma still unclear. Here we study different genetic alteration studies in Moroccan patients with glioblastoma, after selection of articles, only the genes IDH1 / 2, p53 and EGFR were studied.

The IDH1 and IDH2 use NADP + as a cofactor to catalyze the reversible decarboxylation of isocitrate to α-ketoglutarate (α-KG), the latter itself playing an antioxidant role (Hanumantha Rao [@bib0085]). This reaction results from the production of NADPH in the process. NADPH plays an important role in the reproduction of oxidative glutathione (SU [@bib0095]). IDH 1 is more expressed in cytosol and peroxisome. In contrast, the IDH2 is in the mitochondria ([@bib0075]). These enzymes play a vital role in the response to oxidative stress. It has been reported that, the IDH mutations promote cell proliferation and blocks cell differentiation ([@bib0025]). Molecular analysis by sequencing of the IDH1 gene, codon 132, showed a frequency of 12.36% and 36.75% in Moroccan population ([@bib0140]; [@bib0135]). This finding is similar to those reported from other populations in different continents; for example, 10% in America, 20% in the Netherlands and 25% in India. Nonetheless, the outcome of the studies conducted among Moroccans disagree with others performed in Germany (3%), France (5.6%) and China (56%). ([@bib0020]; [@bib0005]; [@bib0080]; [@bib0035]; [@bib0130]; [@bib0185]).

No mutations were observed in the IDH2 gene (172 codons), this result confirmed that this mutation was a secondary glioblastoma marker ([@bib0110]).

The p53 is a transcription factor that plays a crucial role in apoptosis, DNA repair, participates and in the regulation of cell growth ([@bib0160]). The p53 is not a hallmark of tumor types ([@bib0105]), while the expression of p53 was higher in secondary GBM (\> 90%) than in primary (35%) (Kunihiko [@bib0165]). The sequencing of the p53 gene (exons 5 and 8) in a sample of the Moroccan population with primary glioblastoma revealed a low frequency of mutation (8.82%) compared to the Italian (21.2%) and American (23%) ([@bib0060]; [@bib0145] and [@bib0090]).

The EGFR is a tyrosine kinase family, including HER1 also known as EGFR, HER2, HER3 and HER4 ([@bib0175]). It's a proto-oncogene and anti-apoptotic protein that stimulating cell proliferation ([@bib0170]). The EGFR is localized on chromosome 17q22 and divided into 28 exons ([@bib0045]). The expression analysis of the EGFR gene, exon 20, which codes for the tyrosine kinase region showed that the amplification of this gene was 26.15% in the Moroccan population ([@bib0140]). These results are similar to those of the Tunisian population (24%) and discordant with other continents: in Italy (44%), in Spain (53%) and in Portugal (53%) populations ([@bib0150]; [@bib0055]; [@bib0015]; [@bib0155]).

Conclusion {#sec0035}
==========

In this review, including the only three articles dealing with glioblastoma showed that the frequency of IDH1 (R132), IDH2 (R172) and EGFR gene expression (Exon 20) in the Moroccan population coincide and agree with other populations, as described in the discussion. On the contrary, the frequency of the p53 gene (exons 5 and 8) is low compared to the Italian and Japanese populations.

To our knowledge, this is the first Moroccan study on the frequency of altered genes in patients with glioblastoma, based on the studies conducted in this population. Other molecular studies must be conducted on a large number of patients and describe other genetic markers, their impact on the diagnosis, survival and treatment of the Moroccan population.
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[^1]: GBM glioblastomas, pGBM primary glioblastomas, sGBM secondary glioblastomas and ND not determined.
